Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer
Cell Reports · 2024
DOI: 10.1016/j.celrep.2024.114174 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2024. Verfasst von Ryan Blawski und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA. Hauptthemen laut MEDLINE: Histone-Lysine N-Methyltransferase, Breast Neoplasms, Chromatin. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NHGRI NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Activating mutations in PIK3CA are frequently found in estrogen-receptor-positive (ER+) breast cancer, and the combination of the phosphatidylinositol 3-kinase (PI3K) inhibitor alpelisib with anti-ER inhibitors is approved for therapy. We have previously demonstrated that the PI3K pathway regulates ER activity through phosphorylation of the chromatin modifier KMT2D. Here, we discovered a methylation site on KMT2D, at K1330 directly adjacent to S1331, catalyzed by the lysine methyltransferase SMYD2. SMYD2 loss attenuates alpelisib-induced KMT2D chromatin binding and alpelisib-mediated changes in gene expression, including ER-dependent transcription. Knockdown or pharmacological inhibition of SMYD2 sensitizes breast cancer cells, patient-derived organoids, and tumors to PI3K/AKT inhibition and endocrine therapy in part through KMT2D K1330 methylation. Together, our findings uncover a regulatory crosstalk between post-translational modifications that fine-tunes KMT2D function at the chromatin. This provides a rationale for the use of SMYD2 inhibitors in combination with PI3Kα/AKT inhibitors in the treatment of ER+/PIK3CA mutant breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA.
- Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.
- Department of Biochemistry and Molecular Biology, Johns Hopkins School of Public Health, Baltimore, MD 21205, USA.
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
- AstraZeneca, Waltham, MA 02451, USA.
- Antitumor Assessment Core, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Förderung
- NCI NIH HHS
- NHGRI NIH HHS
- NIGMS NIH HHS
- Breast Cancer Alliance
- Fund for Innovation in Cancer Informatics
- National Cancer Institute
Zitieren
APA
Blawski, R., Vokshi, B. H., Guo, X., Kittane, S., Sallaku, M., Chen, W., Gjyzari, M., Cheung, T., Zhang, Y., Simpkins, C., Zhou, W., Kulick, A., Zhao, P., Wei, M., Shivashankar, P., Prioleau, T., Razavi, P., Koche, R., Rebecca, V. W., …, & Toska, E. (2024). Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer. Cell Reports. https://doi.org/10.1016/j.celrep.2024.114174
Vancouver
Blawski R, Vokshi BH, Guo X, Kittane S, Sallaku M, Chen W, et al. Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer. Cell Reports. 2024. doi:10.1016/j.celrep.2024.114174
BibTeX
@article{Blawski2024,
author = {Blawski, Ryan and Vokshi, Bujamin H and Guo, Xinyu and Kittane, Srushti and Sallaku, Mirna and Chen, Wanlu and Gjyzari, Martina and Cheung, Tony and Zhang, Yuhan and Simpkins, Christopher and Zhou, Weiqiang and Kulick, Amanda and Zhao, Peihua and Wei, Meihan and Shivashankar, Pranavkrishna and Prioleau, Tatiana and Razavi, Pedram and Koche, Richard and Rebecca, Vito W and de Stanchina, Elisa and Castel, Pau and Chan, Ho Man and Scaltriti, Maurizio and Cocco, Emiliano and Ji, Hongkai and Luo, Minkui and Toska, Eneda},
title = {Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer},
journal = {Cell Reports},
year = {2024},
doi = {10.1016/j.celrep.2024.114174}
}
EUVIMED